Age 60 years or older without known risk factors for hepatitis B virus infection may complete a HepB vaccine series.Age 60 years or older with known risk factors for hepatitis B virus infection should complete a HepB vaccine series.

* Note: Heplisav-B and PreHevbrio are not recommended in pregnancy due to lack of safety data in pregnant persons.

Settings for exposure, including health care settings targeting services to injection or noninjection drug users or group homes and nonresidential day care facilities for developmentally disabled persons (individual risk factor screening not required).

Pregnancy if at risk for infection or severe outcome from infection during pregnancy.

Close, personal contact with international adoptee (e.g., household or regular babysitting) in first 60 days after arrival from country with high or intermediate endemic hepatitis A (administer dose 1 as soon as adoption is planned, at least 2 weeks before adoptee’s arrival).

Travel in countries with high or intermediate endemic hepatitis A (HepA-HepB may be administered on an accelerated schedule of 3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months).

Work with hepatitis A virus in research laboratory or with nonhuman primates with hepatitis A virus infection.

Chronic liver disease (e.g., persons with hepatitis B, hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase or aspartate aminotransferase level greater than twice the upper limit of normal).

At risk for hepatitis A virus infection: 2-dose series HepA or 3-dose series HepA-HepB as above.

įor more information on Emergency Use Authorization (EUA) indications for COVID-19 vaccines, please visit

See For Janssen COVID-19 Vaccine recipients see COVID-19 schedule at Note: Current COVID-19 schedule available at. Pre-exposure prophylaxis (e.g., monoclonal antibodies) may be considered to complement COVID-19 vaccination.3-dose series at 0, 4, 8 weeks (Moderna) or 3-dose series at 0, 3, 7 weeks (Pfizer-BioNTech).Persons who are moderately or severely immunocompromised 2- or 3- dose primary series and booster ( see notes)ġ dose Tdap each pregnancy 1 dose Td/Tdap for wound management ( see notes)ġ dose Tdap, then Td or Tdap booster every 10 yearsĢ doses for immunocompromising conditions ( see notes)Ģ or 3 doses depending on age at initial vaccination or conditionĢ, 3, or 4 doses depending on vaccine or conditionġ or 2 doses depending on indication, see notes for booster recommendationsĢ or 3 doses depending on vaccine and indication, see notes for booster recommendations

Multiplication table 1 through 20